George Mamo, MD
Urology · Baltimore, MDNPI 1588716641
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,393 and has fallen 83.1% since, to $235 in 2025.
Across 218 payments — averaging $24.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$847
- Johnson & Johnson$407
- Sumitomo Pharma America, Inc.$353
- Urovant Sciences Inc$332
- AbbVie$323
- Medtronic$264
- plus $3K from 35 others
What the payments were for
- Food & beverage$5,03193%
- Education$3557%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 33 | $847 |
| Johnson & Johnson | 12 | $407 |
| Sumitomo Pharma America, Inc. | 16 | $353 |
| Urovant Sciences Inc | 16 | $332 |
| AbbVie(2 entities) | 14 | $323 |
| Medtronic | 8 | $264 |
| Bayer | 9 | $221 |
| Progenics Pharmaceuticals, Inc. | 9 | $216 |
| Boston Scientific | 5 | $213 |
| Ferring Pharmaceuticals Inc. | 14 | $198 |
| Dendreon Pharmaceuticals LLC | 8 | $189 |
| Endo Pharmaceuticals Inc. | 10 | $172 |
| Teleflex LLC | 1 | $139 |
| Immunitybio, Inc. | 1 | $135 |
| Tolmar Pharmaceuticals, Inc. | 6 | $134 |
| Pfizer | 8 | $126 |
| Urogen Pharma, Inc. | 2 | $98 |
| 180 Medical, Inc. | 4 | $97 |
| Myriad Genetic Laboratories, Inc. | 6 | $93 |
| Renovia Inc | 1 | $85 |
| Merck | 4 | $79 |
| Novartis | 3 | $71 |
| Antares Pharma, Inc. | 3 | $66 |
| Neotract Inc. | 3 | $64 |
| Amgen | 2 | $48 |
| Tolmar, Inc. | 2 | $47 |
| Tempus AI, Inc | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 1 | $37 |
| Endo USA, Inc. | 2 | $36 |
| Olympus America Inc. | 1 | $28 |
| Acerus Pharmaceuticals Corporation | 2 | $27 |
| AstraZeneca | 1 | $23 |
| Zyla Life Sciences, Inc. | 1 | $23 |
| Clarus Therapeutics Inc. | 1 | $22 |
| Convatec Inc. | 1 | $22 |
| Accord Healthcare, Inc. | 1 | $21 |
| Vertex | 1 | $20 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $18 |
| Telix Pharmaceuticals | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$147
- UroLift$139
- ANKTIVA$135
- rezum Generator$131
- GEMTESA$120
How this compares
$5,386 in reported general payments places this provider in the 55th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 13 | $195,949 |
| MyrbetriqMirabegron | 62 | $39,708 |
| GemtesaVibegron | 48 | $35,192 |
| Tamsulosin Hcl | 290 | $8,337 |
| Silodosin | 49 | $5,148 |
| Oxybutynin Chloride ErOxybutynin Chloride | 127 | $4,276 |
| Tolterodine Tartrate ErTolterodine Tartrate | 18 | $2,427 |
| Finasteride | 63 | $1,887 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $701 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 37 | $271 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 55 | $192 |
| Ciprofloxacin Hcl | 43 | $184 |
| Oxybutynin Chloride | 12 | $179 |
| Fluconazole | 17 | $150 |
| Tadalafil | 12 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $407 | $195,94913 claims |
| Astellas Pharma US IncMyrbetriq | $847 | $39,70862 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $353 | $35,19248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 274 urology providers in Maryland.
Other urology in Baltimore
- Benjamin LowentrittBaltimore$549K
- Amin HeratiBaltimore$160K
- Max KatesBaltimore$139K
- Arthur BurnettBaltimore$132K
- Aaron WeinbergBaltimore$106K
- Brian MatlagaBaltimore$99K
- Ronald TutroneBaltimore$89K
- Jared WinokerBaltimore$62K
- Jason LevyBaltimore$55K
- Arvin GeorgeBaltimore$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.